CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

C3Spectra is pleased to officially announce its approval by the Federal Communications Commission (FCC) as an Automated Frequency Coordination (AFC) operator. This milestone positions the company to ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent ...

Noninvasive diagnosis of human diseases relies on the detection of molecular markers (probes) in a painless manner. Although extrinsic and intrinsic molecular markers are often used, intrinsic disease ...

Schedule C is an IRS tax form that reports profit or loss from a business. Sole proprietors or single-member LLCs typically use the form. Many, or all, of the products featured on this page are ...